Alfred Habel, MD
Pulmonary Disease · Kenosha, WINPI 1760439608
Payments from drug & device makers
Across 723 payments — averaging $268.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$78K
- AstraZeneca$75K
- GSK$20K
- Viatris Specialty LLC$6K
- Sanofi$5K
- Sunovion Pharmaceuticals Inc.$4K
- plus $6K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 177 | $78,208 |
| AstraZeneca | 181 | $74,944 |
| GSK | 94 | $20,166 |
| Viatris Specialty LLC | 15 | $5,987 |
| Sanofi | 35 | $5,253 |
| Sunovion Pharmaceuticals Inc. | 22 | $3,862 |
| Harmony Biosciences LLC | 40 | $2,185 |
| Jazz Pharmaceuticals Inc. | 61 | $1,228 |
| Avadel CNS Pharmaceuticals, LLC | 14 | $465 |
| Insmed, Inc. | 27 | $447 |
| Regeneron Healthcare Solutions, Inc. | 13 | $282 |
| Verona Pharma, Inc. | 6 | $205 |
| Resmed Corp | 3 | $136 |
| Boehringer Ingelheim | 3 | $123 |
| Mallinckrodt Enterprises LLC | 4 | $120 |
| Novartis | 1 | $100 |
| Amgen | 5 | $90 |
| Itamar Medical Inc | 1 | $84 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Philips North America LLC | 3 | $48 |
| Electromed, Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Pfizer | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Circassia Inc. | 1 | $11 |
How this compares
$194,304 in reported general payments places this provider in the 95th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Kenosha
- Hasnain BawaadamKenosha$714K
- Andrew BraunMadison$1.6M
- Kenneth PresbergMilwaukee$1.4M
- Jonathan KurmanMilwaukee$1.1M
- Stephen HallidayMadison$898K
- Daniel LeonardAppleton$719K
- Mouhammed RihawiMilwaukee$713K
- Mark BarashMilwaukee$498K
- Julie BillerMilwaukee$479K
- Paul LisiCudahy$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.